Table 3.
The characteristics of all patients after PSM
| ALL | ICI + RT | CT + RT | P value | |
|---|---|---|---|---|
| N = 122 | N = 61 | N = 61 | ||
| Age (IQR) | 61.5(55–67) | 62 (55.5–66.5) | 61 (53-67.5) | 0.783 |
| Gender | 1.000 | |||
| Female | 23 (18.9%) | 12 (19.7%) | 11 (18.0%) | |
| Male | 99 (81.1%) | 49 (80.3%) | 50 (82.0%) | |
| PS score | 0.807 | |||
| 1 | 102 (83.6%) | 50 (82.0%) | 52 (85.2%) | |
| 2 | 20 (16.4%) | 11 (18.0%) | 9 (14.8%) | |
| Smoking history | 0.572 | |||
| None | 44 (36.1%) | 24 (39.3%) | 20 (32.8%) | |
| Yes | 78 (63.9%) | 37 (60.7%) | 41 (67.2%) | |
| Primary lesion | 0.365 | |||
| Left lung | 64 (52.5%) | 29 (47.5%) | 35 (57.4%) | |
| Right lung | 58 (47.5%) | 32 (52.5%) | 26 (42.6%) | |
| Surgery of lung | 0.132 | |||
| None | 94 (77.0%) | 51 (83.6%) | 43 (70.5%) | |
| Yes | 28 (23.0%) | 10 (16.4%) | 18 (29.5%) | |
| T stage | 0.918 | |||
| 1 | 11 (9.0%) | 5 (8.2%) | 6 (9.8%) | |
| 2 | 31 (25.4%) | 15 (24.6%) | 16 (26.2%) | |
| 3 | 28 (23.0%) | 13 (21.3%) | 15 (24.6%) | |
| 4 | 47 (38.5%) | 26 (42.6%) | 21 (34.4%) | |
| Unknown | 5 (4.1%) | 2 (3.3%) | 3 (4.9%) | |
| N stage | 0.919 | |||
| 0 | 35 (28.7%) | 16 (26.2%) | 19 (31.1%) | |
| 1 | 8 (6.6%) | 4 (6.6%) | 4 (6.6%) | |
| 2 | 49 (40.2%) | 24 (39.3%) | 25 (41.0%) | |
| 3 | 28 (23.0%) | 16 (26.2%) | 12 (19.7%) | |
| Unknown | 2 (1.6%) | 1 (1.6%) | 1 (1.6%) | |
| Extracranial metastases | 0.362 | |||
| None | 68 (55.7%) | 37 (60.7%) | 31 (50.8%) | |
| Yes | 54 (44.3%) | 24 (39.3%) | 30 (49.2%) | |
| Driver gene | 0.627 | |||
| None | 77 (63.1%) | 37 (60.7%) | 40 (65.6%) | |
| Yes | 11 (9.0%) | 7 (11.5%) | 4 (6.6%) | |
| Unknown | 34 (27.9%) | 17 (27.9%) | 17 (27.9%) | |
| Pathological type | 0.784 | |||
| Adenocarcinoma | 88 (72.1%) | 44 (72.1%) | 44 (72.1%) | |
| Squamous carcinoma | 20 (16.4%) | 11 (18.0%) | 9 (14.8%) | |
| NSCLC(NOS) | 14 (11.5%) | 6 (9.8%) | 8 (13.1%) | |
| Symptoms of BM | 1.000 | |||
| None | 75 (61.5%) | 37 (60.7%) | 38 (62.3%) | |
| Yes | 47 (38.5%) | 24 (39.3%) | 23 (37.7%) | |
| Type of brain radiotherapy | 0.068 | |||
| WBRT | 69 (56.6%) | 29 (47.5%) | 40 (65.6%) | |
| SRS | 53 (43.4%) | 32 (52.5%) | 21 (34.4%) | |
| Sequence of treatment | 0.557 | |||
| Upfront RT | 109(89.3%) | 56(91.8%) | 53(86.9%) | |
| Upfront ICI/CT | 13(10.7%) | 5(8.2%) | 8(13.1%) | |
| Number of BM | 0.928 | |||
| 1 | 51 (41.8%) | 26 (42.6%) | 25 (41.0%) | |
| 2 | 19 (15.6%) | 10 (16.4%) | 9 (14.8%) | |
| >=3 | 52 (42.6%) | 25 (41.0%) | 27 (44.3%) | |
| Size of BM | 0.073 | |||
| < 10 | 20 (16.4%) | 11 (18.0%) | 9 (14.8%) | |
| >=10, < 20 | 45 (36.9%) | 25 (41.0%) | 20 (32.8%) | |
| >=20, < 30 | 21 (17.2%) | 13 (21.3%) | 8 (13.1%) | |
| >=30 | 23 (18.9%) | 10 (16.4%) | 13 (21.3%) | |
| Unknown | 13 (10.7%) | 2 (3.3%) | 11 (18.0%) |
BM, brain metastasis; CT, chemotherapy; ICI, immune checkpoint inhibitor; NSCLC, non-small Cell Lung Cancer; NOS, not otherwise specified; PSM, propensity score matching; RT, radiotherapy; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy